{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T03:12:31Z","timestamp":1793243551124,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T00:00:00Z","timestamp":1709164800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.eclinm.2024.102549","type":"journal-article","created":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T12:52:32Z","timestamp":1710593552000},"page":"102549","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["Survival of adult AML patients treated with chemotherapy in the U.S. population by age, race and ethnicity, sex, calendar-year period, and AML subgroup, 2001\u20132019"],"prefix":"10.1016","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1687-5587","authenticated-orcid":false,"given":"Martha S.","family":"Linet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rochelle E.","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4368-4647","authenticated-orcid":false,"given":"Sara J.","family":"Schonfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline B.","family":"Vo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay M.","family":"Morton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gra\u00e7a M.","family":"Dores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.eclinm.2024.102549_bib1","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood-2011-04-347872","article-title":"Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007","volume":"119","author":"Dores","year":"2012","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.eclinm.2024.102549_bib2","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.3324\/haematol.2012.066100","article-title":"Survival for older patients with acute myeloid leukemia: a population-based study","volume":"97","author":"Oran","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.eclinm.2024.102549_bib3","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1002\/cncr.28129","article-title":"Outcome of older patients with acute myeloid leukemia","volume":"119","author":"Thein","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.eclinm.2024.102549_bib4","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.canep.2017.11.008","article-title":"Improvement of relative survival in elderly patients with acute myeloid leukaemia emerging from population-based cancer registries in Switzerland between 2001 and 2013","volume":"52","author":"Schnegg-Kaufmann","year":"2018","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.eclinm.2024.102549_bib5","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.3324\/haematol.2018.196691","article-title":"Acute myeloid leukemia in very old patients","volume":"103","author":"Lazarevic","year":"2018","journal-title":"Haematologica"},{"issue":"23","key":"10.1016\/j.eclinm.2024.102549_bib6","doi-asserted-by":"crossref","first-page":"4241","DOI":"10.1002\/cncr.32439","article-title":"Temporal patterns and predictors of receiving no acute therapy among older patients with acute myeloid leukemia in the United States: a population level analysis","volume":"125","author":"Zeidan","year":"2019","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.eclinm.2024.102549_bib7","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1182\/bloodadvances.2020001779","article-title":"Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States","volume":"4","author":"Zeidan","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.eclinm.2024.102549_bib8","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00277-015-2351-x","article-title":"Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States","volume":"94","author":"Medeiros","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.eclinm.2024.102549_bib9","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","article-title":"Epidemiology of acute myeloid leukemia: recent progress and enduring challenges","volume":"36","author":"Shallis","year":"2019","journal-title":"Blood Rev"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102549_bib10","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3324\/haematol.2012.064014","article-title":"Survival of European patients diagnosed with myeloid malignancies: a HAEMACARE study","volume":"98","author":"Maynadi\u00e9","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.eclinm.2024.102549_bib11","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.canep.2016.03.011","article-title":"Myeloid malignancies in the real-world: occurrence, progression, and survival in the UK\u2019s population-based Haematological Malignancy Research Network 2004-2015","volume":"42","author":"Roman","year":"2016","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.eclinm.2024.102549_bib12","first-page":"1657","article-title":"Flexible modeling of net survival and cure by AML subtype and age: a French population-based study from FRANCIM","volume":"10","author":"Mounier","year":"2021","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.eclinm.2024.102549_bib13","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1002\/cncr.33458","article-title":"De novo acute myeloid leukemia: a population-based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980 to 2017","volume":"127","author":"Sasaki","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.eclinm.2024.102549_bib14","first-page":"1831","article-title":"Understanding disparities in leukemia: a national study","volume":"23","author":"Patel","year":"2012","journal-title":"Cancer Causes Control"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102549_bib15","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/COC.0b013e31828d7536","article-title":"Age and genetics: how do prognostic factors at diagnosis explain disparities in acute myeloid leukemia?","volume":"38","author":"Patel","year":"2015","journal-title":"Am J Clin Oncol"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102549_bib16","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1158\/2159-8290.CD-20-1579","article-title":"Poor survival and differential impact of genetic features of black patients with acute myeloid leukemia","volume":"11","author":"Bhatnagar","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.eclinm.2024.102549_bib17","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(14)70282-7","article-title":"Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study","volume":"15","author":"Sant","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eclinm.2024.102549_bib18","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000486228","article-title":"Incidence, survival, and risk factors for adults with acute myeloid leukemia not otherwise specified and acute myeloid leukemia with recurrent genetic abnormalities: analysis of the Surveillance, Epidemiology, and End Results (SEER) database, 2001-2013","volume":"139","author":"Song","year":"2018","journal-title":"Acta Haematol"},{"issue":"18","key":"10.1016\/j.eclinm.2024.102549_bib19","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1182\/blood.2019001728","article-title":"Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period","volume":"134","author":"Juliusson","year":"2019","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.eclinm.2024.102549_bib20","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/cncr.29319","article-title":"Improvements in early death rate in 9,380 acute myeloid leukemia patients following initial therapy: a SEER database analysis","volume":"121","author":"Percival","year":"2015","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.eclinm.2024.102549_bib21","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.3109\/10428194.2014.885517","article-title":"Treatment of de novo acute myeloid leukemia in the United States: a report from the patterns of care program","volume":"55","author":"Doria-Rose","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102549_bib22","doi-asserted-by":"crossref","first-page":"721","DOI":"10.6004\/jnccn.2019.0028","article-title":"Acute myeloid leukemia, version 3.2019 NCCN clinical practice guidelines in oncology","volume":"17","author":"Tallman","year":"2019","journal-title":"J\u00a0Natl Compr Cancer Netw"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102549_bib23","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.clml.2023.03.012","article-title":"FDA analysis of ineligibility for acute myeloid leukemia clinical trials by race and ethnicity","volume":"23","author":"Pulte","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"10.1016\/j.eclinm.2024.102549_bib24","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1056\/NEJMp2106089","article-title":"Treatment of older adults with cancer \u2013 addressing gaps in evidence","volume":"385","author":"Bertagnolli","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.eclinm.2024.102549_bib25","first-page":"2813","article-title":"How I treat AML incorporating the updated classifications and guidelines","volume":"141","author":"El Chaer","year":"2023","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102549_bib27","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international panel on behalf of the European LeukemiaNET","volume":"115","author":"D\u00f6hner","year":"2010","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102549_bib28","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.ejca.2008.11.018","article-title":"EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary","volume":"45","author":"Sant","year":"2009","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.eclinm.2024.102549_bib30","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1093\/jnci\/djad069","article-title":"Cancer mortality rates by racial\/ethnic groups in the United States, 2018-2020","volume":"115","author":"Haque","year":"2023","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.eclinm.2024.102549_bib31","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/bjh.17213","article-title":"Temporal changes in survival among adult patients with acute myeloid leukemia in the period 2000-2016: a Danish population-based study","volume":"193","author":"Jakobsen","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.eclinm.2024.102549_bib32","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/bjh.16359","article-title":"Twenty-five years of UK trials in acute myeloid leukaemia: what have we learned?","volume":"188","author":"Burnett","year":"2020","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102549_bib33","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1080\/10428194.2023.2165394","article-title":"Comorbidity burden and outcomes of older adults with acute promyelocytic leukemia: a national cancer database analysis of 2221 patients","volume":"64","author":"Dhakal","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102549_bib34","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12885-023-10612-z","article-title":"Acute promyelocytic leukaemia: population-based study of epidemiology and outcome with ATRA and oral-ATO from 1991 to 2021","volume":"23","author":"Gill","year":"2023","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102549_bib35","doi-asserted-by":"crossref","first-page":"142","DOI":"10.2991\/chi.k.210703.001","article-title":"History of promyelocytic leukemia","volume":"3","author":"Sanz","year":"2021","journal-title":"Clin Hematol Int"},{"issue":"8","key":"10.1016\/j.eclinm.2024.102549_bib36","first-page":"733","article-title":"Treatment of acute promyelocytic leukemia without cytotoxic chemotherapy","volume":"25","author":"Park","year":"2011","journal-title":"Oncology (Williston Park)"},{"issue":"19","key":"10.1016\/j.eclinm.2024.102549_bib37","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.1002\/cncr.31674","article-title":"Adult leukemia survival trends in the United States by subtype: a population-based registry study of 370,994 patients diagnosed during 1995-2009","volume":"124","author":"Bailey","year":"2018","journal-title":"Cancer"},{"issue":"15","key":"10.1016\/j.eclinm.2024.102549_bib38","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1182\/blood-2017-04-778225","article-title":"Racial and ethnic disparities in hematologic malignancies","volume":"130","author":"Kirtane","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102549_bib39","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1038\/s41375-023-01884-2","article-title":"Validation and refinement of the 2022 European LeukemiaNET genetic risk stratification of acute myeloid leukemia","volume":"37","author":"Rausch","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.eclinm.2024.102549_bib40","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","article-title":"Acute myeloid leukemia","volume":"392","author":"Short","year":"2018","journal-title":"Lancet"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024001287?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024001287?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T21:48:11Z","timestamp":1760737691000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537024001287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":38,"alternative-id":["S2589537024001287"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102549","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Survival of adult AML patients treated with chemotherapy in the U.S. population by age, race and ethnicity, sex, calendar-year period, and AML subgroup, 2001\u20132019","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102549","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102549"}}